GlassScriptPhysician profile
Lloyd A Pierre
NPI 1417007162
$4,443.32
in general payments reported to CMS, 2019-2025
32 companies · $1,142 in 2025
The $1,142 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $209 · 2020: $145 · 2021: $697 · 2022: $757 · 2023: $692 · 2024: $802 · 2025: $1,142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,636.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,635.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,242.72 | 2021-2025 | Airsupra, Breztri, Bydureon |
| Abbvie INC. | $1,032.60 | 2021-2025 | |
| Pfizer INC. | $388.84 | 2020-2025 | |
| Glaxosmithkline, LLC. | $346.23 | 2020-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $202.10 | 2019-2024 | Xifaxan |
| Hologic Sales and Service, LLC | $181.98 | 2019-2025 | Aptima, Thinprep 2000 Processor, Third Wave |
| Biohaven Pharmaceuticals, INC. | $171.02 | 2021 | |
| Lilly USA, LLC | $66.16 | 2021-2025 | Mounjaro, Zepbound |
| Seqirus USA INC | $64.84 | 2024-2025 | Fluad, Flucelvax |
| Therapeuticsmd, INC. | $63.95 | 2019-2022 | |
| Novo Nordisk INC | $59.87 | 2025 | Ozempic, Wegovy, Rybelsus |
| Amneal Pharmaceuticals LLC | $57.99 | 2025 | Unithroid |
| Exact Sciences Corporation | $48.28 | 2025 | Cologuard Collection Kit |
| Inspire Medical Systems, INC. | $48.00 | 2025 | Inspire |
| Janssen Pharmaceuticals, INC | $46.36 | 2025 | Spravato |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $43.89 | 2021-2025 | Vaxneuvance, Enflonsia, Gardasil 9 |
| Novartis Pharmaceuticals Corporation | $39.56 | 2022 | |
| Vbi Vaccine (Delaware) INC. | $38.87 | 2022-2023 | Prehevbrio |
| Genentech USA, INC. | $35.28 | 2020 | |
| Mayne Pharma Commercial LLC | $30.18 | 2024-2025 | |
| Axsome Therapeutics, INC. | $30.06 | 2025 | Symbravo |
| Avion Pharmaceuticals | $29.95 | 2021-2022 | |
| Ultragenyx Pharmaceutical INC. | $27.93 | 2022-2023 | |
| Kyowa Kirin, INC. | $23.14 | 2023 | Crysvita |
| Otsuka America Pharmaceutical, INC. | $23.02 | 2025 | Rexulti |
| Acella Pharmaceuticals, LLC | $16.67 | 2024 | NP Thyroid 60 |
| Sanofi-Aventis U.S. LLC | $16.55 | 2025 | |
| Currax Pharmaceuticals LLC | $15.05 | 2022 | |
| Mylan Specialty L.P. | $14.56 | 2021 | |
| Ascend Therapeutics US, LLC | $12.96 | 2023 | |
| Ibsa Pharma INC. | $12.51 | 2022 | |
| Allergan, INC. | $12.20 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lloyd Pierre listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.